Howard Fillit

Summary

Affiliation: Institute for the Study of Aging
Country: USA

Publications

  1. ncbi request reprint Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews
    H M Fillit
    Institute for the Study of Aging, New York, NY 10153, USA
    Am J Manag Care 5:587-94. 1999
  2. ncbi request reprint The costs of vascular dementia: a comparison with Alzheimer's disease
    Howard Fillit
    Institute for the Study of Aging, New York, NY 10153, USA
    J Neurol Sci 203:35-9. 2002
  3. ncbi request reprint Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias
    Howard Fillit
    Institute for the Study of Aging, New York, New York 10153, USA
    J Am Geriatr Soc 50:1871-8. 2002
  4. ncbi request reprint The role of hormone replacement therapy in the prevention of Alzheimer disease
    Howard M Fillit
    The Institute for the Study of Aging, Inc, New York, NY 10153, USA
    Arch Intern Med 162:1934-42. 2002
  5. ncbi request reprint Achieving and maintaining cognitive vitality with aging
    Howard M Fillit
    Institute for the Study of Aging, Inc, New York, NY 10153, USA
    Mayo Clin Proc 77:681-96. 2002
  6. ncbi request reprint Barriers to drug discovery and development for Alzheimer disease
    Howard M Fillit
    The Institute for the Study of Aging, Inc, New York, New York, USA
    Alzheimer Dis Assoc Disord 16:S1-8. 2002
  7. ncbi request reprint Impact of donepezil on caregiving burden for patients with Alzheimer's disease
    H M Fillit
    Institute for the Study of Aging, New York, New York 10153, USA
    Int Psychogeriatr 12:389-401. 2000
  8. ncbi request reprint Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study
    Shaoli Lu
    Institute for the Study of Aging, New York, New York 10019, USA
    Am J Geriatr Pharmacother 3:92-102. 2005
  9. ncbi request reprint Economics of dementia and pharmacoeconomics of dementia therapy
    Howard Fillit
    Institute for the Study of Aging, Inc, New York, New York 10019, USA
    Am J Geriatr Pharmacother 3:39-49. 2005
  10. doi request reprint Cardiovascular risk factors and dementia
    Howard Fillit
    Institute for the Study of Aging and the Alzheimer s Drug Discovery Foundation, New York, New York 10019, USA
    Am J Geriatr Pharmacother 6:100-18. 2008

Detail Information

Publications31

  1. ncbi request reprint Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews
    H M Fillit
    Institute for the Study of Aging, New York, NY 10153, USA
    Am J Manag Care 5:587-94. 1999
    ..To examine the effects of medication reviews by primary care physicians on prescriptions written for elderly members of a Medicare managed care organization who were at risk for polypharmacy...
  2. ncbi request reprint The costs of vascular dementia: a comparison with Alzheimer's disease
    Howard Fillit
    Institute for the Study of Aging, New York, NY 10153, USA
    J Neurol Sci 203:35-9. 2002
    ..To estimate the costs of Medicare patients with vascular dementia (VaD). To compare the costs of VaD to Alzheimer's disease (AD) and controls without dementia...
  3. ncbi request reprint Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias
    Howard Fillit
    Institute for the Study of Aging, New York, New York 10153, USA
    J Am Geriatr Soc 50:1871-8. 2002
    ....
  4. ncbi request reprint The role of hormone replacement therapy in the prevention of Alzheimer disease
    Howard M Fillit
    The Institute for the Study of Aging, Inc, New York, NY 10153, USA
    Arch Intern Med 162:1934-42. 2002
    ..Ongoing clinical studies may help to determine the role of estrogen in the cognitive function of postmenopausal women and in the prevention of AD...
  5. ncbi request reprint Achieving and maintaining cognitive vitality with aging
    Howard M Fillit
    Institute for the Study of Aging, Inc, New York, NY 10153, USA
    Mayo Clin Proc 77:681-96. 2002
    ..The data presented in this review should interest physicians who provide preventive care management to middle-aged and older individuals who seek to maintain cognitive vitality with aging...
  6. ncbi request reprint Barriers to drug discovery and development for Alzheimer disease
    Howard M Fillit
    The Institute for the Study of Aging, Inc, New York, New York, USA
    Alzheimer Dis Assoc Disord 16:S1-8. 2002
    ..The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail...
  7. ncbi request reprint Impact of donepezil on caregiving burden for patients with Alzheimer's disease
    H M Fillit
    Institute for the Study of Aging, New York, New York 10153, USA
    Int Psychogeriatr 12:389-401. 2000
    ..In conclusion, better management of AD symptoms through donepezil treatment may reduce the burden of caregiving, providing physicians with a pharmacologic approach to improving quality of life for AD patients and their families...
  8. ncbi request reprint Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study
    Shaoli Lu
    Institute for the Study of Aging, New York, New York 10019, USA
    Am J Geriatr Pharmacother 3:92-102. 2005
    ..However, there are limited studies examining the impact on health care costs of cholinesterase inhibitors prescribed in routine clinical practice...
  9. ncbi request reprint Economics of dementia and pharmacoeconomics of dementia therapy
    Howard Fillit
    Institute for the Study of Aging, Inc, New York, New York 10019, USA
    Am J Geriatr Pharmacother 3:39-49. 2005
    ..In 1997, the cost of managing patients with Alzheimer's disease and other dementias was estimated at US dollar 100 billion. Direct medical costs are compounded by indirect costs of care, including unpaid care and loss of earnings...
  10. doi request reprint Cardiovascular risk factors and dementia
    Howard Fillit
    Institute for the Study of Aging and the Alzheimer s Drug Discovery Foundation, New York, New York 10019, USA
    Am J Geriatr Pharmacother 6:100-18. 2008
    ..Evidence is accumulating to suggest that cardiovascular disease (CVD) risk factors may be instrumental in the development of dementia...
  11. ncbi request reprint Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population
    Jerrold Hill
    Institute for the Study of Aging, New York, NY 10019, USA
    J Alzheimers Dis 8:43-50. 2005
    ..While vascular dementia (VaD) is the second most prevalent dementia diagnosis, little is known about healthcare use and costs for VaD...
  12. ncbi request reprint The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementias
    Howard Fillit
    Institute for the Study of Aging, Inc, New York, NY 10453, USA
    Alzheimer Dis Assoc Disord 18:S24-9. 2004
    ....
  13. ncbi request reprint Validation of a brief screen for cognitive impairment (BSCI) administered by telephone for use in the medicare population
    Jerrold Hill
    Institute for the Study of Aging, New York, New York 10019, USA
    Dis Manag 8:223-34. 2005
    ..The use of brief screening instruments for dementia, such as the one validated here, will be increasingly important for the effective management of dementia and other chronic diseases where dementia is a coexisting condition...
  14. ncbi request reprint Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy
    Howard Fillit
    Institute for the Study of Aging, New York, USA
    Fam Med 34:528-35. 2002
    ..This study analyzed the relationship between co-morbid conditions and health care utilization and costs for patients with AD and estimated costs by stage of disease and receipt of pharmacotherapy...
  15. ncbi request reprint The effect of donepezil therapy on health costs in a Medicare managed care plan
    Jerrold W Hill
    Institute for the Study for Aging, New York City, USA
    Manag Care Interface 15:63-70. 2002
    ..By improving cognitive and daily functioning, donepezil may lower costs by improving medical management...
  16. ncbi request reprint Biomarkers of aging: from primitive organisms to humans
    Robert N Butler
    International Longevity Center USA, 60 E 86th St, New York, NY 10028, USA
    J Gerontol A Biol Sci Med Sci 59:B560-7. 2004
    ..Finally, and significantly, it is difficult to obtain funding for this research...
  17. ncbi request reprint Neurogenesis as a therapeutic strategy for cognitive aging and Alzheimer's disease
    Gunnar Gouras
    Dept of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, NY, USA
    Curr Alzheimer Res 3:3. 2006
  18. ncbi request reprint Cardiovascular disease risk factors and cognitive impairment
    David T Nash
    Upstate Medical University, Syracuse Preventive Cardiology, Syracuse, New York, USA
    Am J Cardiol 97:1262-5. 2006
    ..Antioxidants, fatty acids, and micronutrients may have a role, and diets rich in fruits and vegetables and other dietary approaches may improve the outlook for patients considered at risk for cognitive impairment...
  19. doi request reprint Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease
    Howard Fillit
    Brookdale Department of Geriatrics and Adult Development, The Mount Sinai School of Medicine, New York, NY, USA
    J Am Med Dir Assoc 11:636-644. 2010
    ..To estimate the effect of memantine discontinuation for a nonmedical reason (eg, formulary restriction or family decision) on the health status of nursing home (NH) residents with Alzheimer's disease (AD)...
  20. ncbi request reprint Intravenous immunoglobulins for Alzheimer's disease
    Howard Fillit
    Institute for the Study of Aging, New York, NY, USA
    Lancet Neurol 3:704. 2004
  21. doi request reprint The frailty identity crisis
    Howard Fillit
    Institute for the Study of Aging, Mopunt Sinai Medical Center, New York, New York, USA
    J Am Geriatr Soc 57:348-52. 2009
    ..Early detection, management, and counseling of individuals experiencing the frailty identity crisis has implications for the health and quality of life of frail individuals, their loved ones and caregivers, and society...
  22. doi request reprint Drug discovery and the prevention of Alzheimer's disease
    Howard Fillit
    Executive Director, The Alzheimer s Drug Discovery Foundation, New York, NY, USA
    Alzheimers Dement 4:S26-8. 2008
    ..Ultimately, the development of truly effective disease-modifying drugs through accelerated drug discovery is the only real pathway to primary prevention...
  23. ncbi request reprint Recommendations for best practices in the treatment of Alzheimer's disease in managed care
    Howard M Fillit
    Alzheimer s Drug Discovery Foundation and Institute for the Study of Aging New York, New York 10019, USA
    Am J Geriatr Pharmacother 4:S9-S24; quiz S25-S28. 2006
    ..However, these clinical guidelines have not been updated in the past few years...
  24. ncbi request reprint Strategies for drug discovery for cognitive aging and Alzheimer's disease
    Howard M Fillit
    The Institute for the Study of Aging, New York, NY, USA
    J Mol Neurosci 19:1-3. 2002
  25. doi request reprint Practicality of a computerized system for cognitive assessment in the elderly
    Howard M Fillit
    Institute for the Study of Aging, Inc, New York, NY, USA
    Alzheimers Dement 4:14-21. 2008
    ..This study evaluated its feasibility for assessment of the elderly...
  26. ncbi request reprint Drug discovery for Alzheimer's disease: filling the pipeline
    Antony R Horton
    Curr Alzheimer Res 4:501-2. 2007
  27. ncbi request reprint Advancing drug discovery for Alzheimer's disease
    Howard M Fillit
    The Institute for the Study of Aging, 1414 Avenue of the Americas, Suite 1502, New York, NY, USA
    Curr Alzheimer Res 2:105-7. 2005
  28. ncbi request reprint Tau and Alzheimer's disease: the long road to anti-tangle therapeutics
    Howard M Fillit
    The Institute for the Study of Aging, New York, NY, USA
    J Mol Neurosci 19:249-50. 2002
  29. ncbi request reprint Autoimmune markers in HIV-associated dementia
    Steven E Schutzer
    Department of Medicine, UMDNJ New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
    J Neuroimmunol 138:156-61. 2003
    ..Reactivity against control tissue was negative. Though the etiopathogenetic relation of these antibrain antibodies remains to be delineated, the data suggest that they may be a marker of HAD...
  30. ncbi request reprint Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease
    Lorenzo M Refolo
    Institute for the Study of Aging, New York, NY 10153, USA
    J Mol Neurosci 23:151-5. 2004
    ..Putative pathological functions, or risk-factor activities, of apoE4 include its role in beta-amyloid deposition, neurofibrillary tangle formation, synaptic loss, lipid dysfunction, neuroinflammation, and oxidative stress...
  31. ncbi request reprint Drug discovery for Alzheimer's disease: the end of the beginning
    Lorenzo M Refolo
    The Institute for the Study of Aging, New York, NY, USA
    J Mol Neurosci 24:1-8. 2004